The Opportunity
The pharmaceutical industry is increasingly looking toward academia for new product opportunities. Research collaborations are a cost-effective way to develop novel therapeutic approaches in a rapidly evolving healthcare environment. Likewise, the National Institute of Health (NIH) is emerging as a strong player in translational medicine. The NIH provides nearly $30 billion in non-dilutive funding to researchers across the nation every year.
The Challenge
Angel investors and venture capital funds have moved toward later-stage assets, especially with respect to drug therapies. An early-stage technology may have significant potential, but not have the comprehensive data package or the go-to-market plan required to raise the funds needed. As a result, many promising projects fail to be realized.
The Therapeutic "Valley of Death"
The Solution
TSRL, Inc. is building on its successful history of developing technologies through the NIH SBIR program by collaborating with academic researchers and entrepreneurs to provide access to non-dilutive funding. Funded projects will have access to experienced pharmaceutical scientists and business professionals, wet-lab space, and other resources to drive promising projects to an Investigational New Drug (IND) application.
Our Technology Accelerator Process
For more information, contact Business Development at bd@tsrlinc.com
